Innoviva Net Change in Short-term Investments 2012-2026 | INVA

Innoviva net change in short-term investments from 2012 to 2026. Net change in short-term investments can be defined as the net cash flows from the sale and purchase of investments defined to be short-term, generally with maturities of less than one year from the purchase date.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Innoviva Annual Net Change in Short-term Investments
(Millions of US $)
2025 N/A
2024 N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A
2014 N/A
2013 N/A
2012 N/A
2011 N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.760B $0.411B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $887.629B 38.81
Johnson & Johnson (JNJ) United States $574.358B 22.08
AbbVie (ABBV) United States $367.673B 20.79
Roche Holding AG (RHHBY) Switzerland $318.782B 0.00
Merck (MRK) United States $299.893B 13.54
Novartis AG (NVS) Switzerland $293.951B 17.16
Novo Nordisk (NVO) Denmark $167.527B 9.60
Pfizer (PFE) United States $153.074B 8.33
Sanofi (SNY) France $114.048B 10.56
Bayer (BAYRY) Germany $46.178B 8.70